Related Experiment Videos
[Citrate therapy in treating urate nephrolithiasis].
Urologiia I Nefrologiia
|November 19, 2002
Summary
Citrate therapy effectively treats urate nephrolithiasis in many patients, whether used alone or with other treatments. Blemaren is recommended as a highly beneficial citrate drug for managing kidney stones.
Area of Science:
- Nephrology
- Urology
- Pharmacology
Context:
- Urate nephrolithiasis is a common condition requiring effective treatment.
- Current treatment strategies include invasive and remote interventions.
- Citrate therapy offers a potential non-invasive approach.
Purpose:
- To evaluate the efficacy of citrate therapy in patients with urate nephrolithiasis.
- To compare the effectiveness of citrate monotherapy versus combination therapy.
- To identify the most beneficial citrate drug for managing urate stones.
Summary:
- Citrate therapy was administered to 483 patients diagnosed with urate nephrolithiasis.
- A positive therapeutic response was observed in patients receiving citrate as monotherapy.
- Combination therapy involving citrate with invasive or remote treatments also yielded good results.
- The drug Blemaren (ESPARMA, Germany) was identified as the most advantageous among the evaluated citrate medications.
Impact:
- Citrate therapy presents a viable and effective treatment option for urate nephrolithiasis.
- The findings support the use of Blemaren as a preferred citrate agent.
- This research may influence clinical guidelines for managing urate kidney stones.